机构地区:[1]State Key Laboratory of Bioactive Molecules and Druggability Assessment,Jinan University,Guangzhou 510632,China [2]Guangdong Province Key Laboratory of Pharmacodynamic Constituents of Traditional Chinese Medicine and New Drugs Research,College of Pharmacy,Jinan University,Guangzhou 510632,China [3]School of Medicine,Jinan University,Guangzhou 510632,China [4]School of Traditional Chinese Medicine,Jinan University,Guangzhou 510630,China [5]The First Affiliated Hospital of Jinan University,Guangzhou 510632,China [6]State Key Laboratory of Chemical Oncogenomics,Guangdong Provincial Key Laboratory of Chemical Biology,Tsinghua Shenzhen International Graduate School,Shenzhen 518055,China
出 处:《Acta Pharmaceutica Sinica B》2024年第2期682-697,共16页药学学报(英文版)
基 金:supported by the National Natural Science Foundation of China(82273941,81973340,82204427,81803566,82003796,81773758);Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program(2017BT01Y036,China);Natural Science Foundation of Guangdong Province(2022A1515011813,2021A1515110242,2020A1515010071,2019A1515010144,2019A1515110543,2019A1515011934,China);Ministry of Science and Technology of China(2018ZX09711001-008-008);National high-level personnel of special support program(Zhang Dongmei),National Key R&D Program of China(2017YFC 1703800);Technology Key Project of Guangdong Province(2020B1111110004,China);Guangdong Province Key Laboratory of Pharmacodynamic Constituents of Traditional Chinese Medicine and New Drugs Research,College of Pharmacy(2020B1212060076,China);Special Funds for the Cultivation of Guangdong College Students’Scientifc and Technological Innovation(“Climbing Program”Special Funds)(pdjh2021a0052,China);Science and Technology Projects in Guangzhou(2023A03J0602,202201010173,202102070001,202002030010,China);Young S&T Talent Training Program of Guangdong Provincial Association for S&T,China(SKXRC202216);Clinical Frontier Technology Program of the First Affiliated Hospital of Jinan University(JNU1AF-CFTP-2022-a01227,China);China Postdoctoral Science Foundation(2022M 711345,China).
摘 要:Lymphatic metastasis is the main metastatic route for colorectal cancer, which increases the risk of cancer recurrence and distant metastasis. The properties of the lymph node metastatic colorectal cancer(LNM-CRC) cells are poorly understood, and effective therapies are still lacking. Here, we found that hypoxia-induced fibroblast activation protein alpha(FAPα) expression in LNM-CRC cells. Gain-or loss-function experiments demonstrated that FAPα enhanced tumor cell migration, invasion, epithelial-mesenchymal transition, stemness, and lymphangiogenesis via activation of the STAT3 pathway. In addition, FAPα in tumor cells induced extracellular matrix remodeling and established an immunosuppressive environment via recruiting regulatory T cells, to promote colorectal cancer lymph node metastasis(CRCLNM). Z-GP-DAVLBH, a FAPα-activated prodrug, inhibited CRCLNM by targeting FAPα-positive LNM-CRC cells. Our study highlights the role of FAPα in tumor cells in CRCLNM and provides a potential therapeutic target and promising strategy for CRCLNM.
关 键 词:LYMPHATICMETASTASIS Colorectal cancer Fibroblastactivation proteinα FAPα-activated prodrug Epithelial-mesenchymal
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...